Oncology Pharma Inc. (ONPH) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oncology Pharma Inc. (ONPH) trades at $0.0523. Oncology Pharma Inc. is a San Francisco-based biotechnology company focused on developing, manufacturing, and commercializing oncology therapeutics. Market cap: $1.43M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for ONPH: ONPH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ONPH against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ONPH: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Oncology Pharma Inc. (ONPH) Healthcare & Pipeline Overview
Oncology Pharma Inc. is a biotechnology firm specializing in the development and commercialization of oncology therapeutics, with a strategic collaboration for COVID-19 treatment exploration. Incorporated in 1993 and headquartered in San Francisco, the company operates within the high-growth healthcare sector, addressing significant unmet medical needs.
What Is the Investment Thesis for ONPH?
Oncology Pharma Inc. operates within the high-growth and critical oncology therapeutics sector, addressing significant unmet medical needs. The company's dedicated focus on developing and commercializing cancer treatments positions it within a market characterized by continuous innovation and substantial demand. A key value driver is its collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring COVID-19 treatments, which represents a potential diversification of its therapeutic pipeline and revenue streams beyond oncology. However, as a smaller pharmaceutical company with a market capitalization of $1.43M and a beta of -6.55, ONPH faces inherent risks common to drug development, including the lengthy and costly process of clinical trials, the uncertainty of regulatory approvals, and the ongoing challenge of securing adequate funding for research and development. Investors should monitor the progress of its therapeutic development programs and any future financing activities, as successful advancement through clinical stages or strategic partnerships could serve as significant growth catalysts.
Based on FMP financials and quantitative analysis
ONPH Key Highlights
The company maintains a market capitalization of $1.43M, reflecting its current valuation within the biotechnology sector.
- Oncology Pharma Inc. reports a Beta of -6.55, indicating a historical inverse relationship with broader market movements.
- The company operates with a lean structure, employing 1 individual, as managed by its CEO, George Malesek.
- Oncology Pharma Inc. does not currently offer a dividend yield, consistent with many development-stage biotechnology firms.
- The company was incorporated in 1993 and strategically rebranded from SourcingLink.net Inc. to Oncology Pharma Inc. in June 2019, signaling a clear shift to its current oncology focus.
Who Are ONPH's Competitors?
ONPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ONPH's Key Strengths?
Dedicated focus on the high-growth oncology therapeutics sector.
- Strategic collaboration with Kalos Therapeutics Inc. for COVID-19 treatment exploration.
- Incorporated since 1993, indicating long-standing presence in the corporate landscape.
- Headquartered in San Francisco, a hub for biotechnology innovation.
What Are ONPH's Weaknesses?
Extremely small operational scale with only 1 employee.
- Market capitalization of $1.43M suggests minimal market valuation and potential liquidity issues.
- High inherent risks associated with drug development, including lengthy clinical trials and regulatory hurdles.
- Unknown disclosure status on the OTC market, limiting investor transparency.
What Could Drive ONPH Stock Higher?
ONPH catalyst: **Advancement of Oncology Pipeline**: Any public announcement regarding the successful progression of an oncology drug candidate through preclinical or clinical trial stages could serve as a significant catalyst, signaling potential future commercialization.
- **Progress in COVID-19 Treatment Collaboration**: Positive updates or milestones achieved in the collaboration with Kalos Therapeutics Inc. for COVID-19 treatment development, such as preclinical results or initiation of clinical trials, could generate investor interest.
- **Securing New Funding or Strategic Partnerships**: Announcements of successful capital raises, significant grants, or new strategic partnerships with larger pharmaceutical companies could provide the necessary resources to accelerate drug development and validate the company's programs.
What Are the Key Risks for ONPH?
Negative return on equity (-1.1%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- **Drug Development and Regulatory Risks**: The inherent challenges of drug development, including the high failure rate in clinical trials, lengthy timelines, and stringent regulatory approval processes, pose a significant ongoing risk to Oncology Pharma Inc.'s prospects.
- **Funding and Liquidity Challenges**: As a small company with a $1.43M market cap, securing adequate and consistent funding for costly research and development, especially for clinical trials, remains an ongoing challenge. Its OTC Other listing exacerbates liquidity concerns.
- **Competitive Landscape**: The biotechnology and oncology sectors are highly competitive, with numerous well-funded companies vying for market share. Oncology Pharma Inc. faces the potential risk of being outpaced by competitors with greater resources or more advanced pipelines.
- **Reliance on Collaboration Success**: The success of the COVID-19 treatment exploration is dependent on the collaboration with Kalos Therapeutics Inc. Any issues or setbacks with this partnership could negatively impact the company's diversification efforts.
- **OTC Market Risks**: The company's trading on the OTC Other tier presents ongoing risks related to extreme illiquidity, lack of transparency, potential for price manipulation, and difficulty in obtaining reliable financial and operational information for investors.
What Are the Growth Opportunities for ONPH?
- Growth opportunity 1: **Expansion in Oncology Therapeutics Market**: The global oncology therapeutics market is projected for substantial growth, driven by an aging population, increasing cancer prevalence, and advancements in treatment modalities. Oncology Pharma Inc.'s core focus on developing oncology therapeutics positions it to potentially capitalize on this expanding market. Successfully advancing drug candidates through clinical trials and securing regulatory approvals for novel cancer treatments could unlock significant revenue streams and market share within this high-demand sector, addressing critical unmet medical needs for patients worldwide.
- Growth opportunity 2: **Leveraging Strategic Collaboration for COVID-19**: The collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring COVID-19 treatment opportunities presents a distinct growth avenue. This partnership allows Oncology Pharma Inc. to diversify its therapeutic pipeline beyond oncology, tapping into a global health priority. Successful development and commercialization of a COVID-19 therapeutic could provide a significant and immediate market opportunity, leveraging existing pharmaceutical development capabilities and potentially generating substantial revenue, thereby strengthening the company's financial position and market relevance.
- Growth opportunity 3: **Pipeline Development and Diversification**: While specific pipeline details are limited, the company's stated mission to 'develop, manufacture, and commercialize therapeutics' implies an ongoing effort to build and advance a robust drug pipeline. Strategic investments in research and development to identify and pursue novel drug candidates for various cancer types or other high-need therapeutic areas could drive long-term growth. Expanding the pipeline with differentiated assets, potentially through in-house discovery or further licensing agreements, is crucial for sustained relevance and market penetration in the competitive biotechnology landscape.
- Growth opportunity 4: **Strategic Partnerships and Licensing**: Given the capital-intensive nature of drug development, forming additional strategic partnerships or out-licensing agreements could be a significant growth driver. Collaborations with larger pharmaceutical companies can provide access to greater financial resources, specialized expertise, and broader distribution networks, accelerating the development and commercialization of Oncology Pharma Inc.'s therapeutic candidates. Such partnerships can also validate the scientific merit of its programs and reduce the financial burden and risk associated with late-stage clinical trials.
- Growth opportunity 5: **Addressing Unmet Medical Needs in Cancer**: Many cancer types still lack effective or curative treatments, representing substantial unmet medical needs. Oncology Pharma Inc.'s focus on oncology therapeutics inherently targets these areas. By successfully developing therapies that offer improved efficacy, reduced side effects, or address resistant forms of cancer, the company can capture significant market share. Innovation in this space, particularly in areas like targeted therapies, immunotherapies, or novel drug delivery systems, positions the company to make a meaningful impact on patient outcomes and achieve commercial success.
What Are ONPH's Competitive Advantages?
- Specialized focus within the oncology therapeutics sector, addressing complex diseases.
- Potential intellectual property through patents on drug candidates and manufacturing processes, if applicable.
- Strategic collaboration and licensing agreement with Kalos Therapeutics Inc. for COVID-19 treatment opportunities.
- Expertise in navigating the rigorous drug development and regulatory approval processes in the biotechnology industry.
What Does ONPH Do?
Oncology Pharma Inc., incorporated in 1993 and based in San Francisco, California, is an oncology company dedicated to the development, manufacturing, and commercialization of therapeutics. Initially known as SourcingLink.net Inc., the company underwent a strategic rebranding in June 2019, changing its name to Oncology Pharma Inc. to better reflect its focused mission within the healthcare sector. The company's primary business revolves around identifying, developing, and bringing to market pharmaceutical products aimed at treating various forms of cancer. This core focus places Oncology Pharma Inc. within the dynamic and research-intensive biotechnology industry, characterized by significant investment in R&D and a long product development cycle. Beyond its oncology initiatives, Oncology Pharma Inc. has diversified its therapeutic exploration through a notable collaboration and licensing agreement with Kalos Therapeutics Inc. This partnership is specifically geared towards investigating and developing potential treatment opportunities for the COVID-19 virus, indicating an adaptive approach to public health challenges and leveraging its pharmaceutical development capabilities into new areas. As a developer of therapeutics, the company's operational model involves navigating complex regulatory pathways, conducting clinical trials, and ultimately aiming for commercialization of its drug candidates. While specific details on its pipeline stages are not publicly detailed, its stated objective positions it as a participant in the global effort to advance medical treatments.
What Products and Services Does ONPH Offer?
- Develops novel therapeutic compounds for the treatment of various diseases.
- Focuses primarily on the oncology sector, aiming to create new cancer treatments.
- Manufactures pharmaceutical products, likely through contract manufacturing organizations or in-house capabilities.
- Commercializes approved therapeutics, bringing them to market for patient use.
- Engages in research and development to identify and advance drug candidates.
- Holds a collaboration and licensing agreement with Kalos Therapeutics Inc. for COVID-19 treatment exploration.
How Does ONPH Make Money?
- Revenue generation primarily through the commercialization and sales of approved therapeutic drugs.
- Potential for milestone payments and royalties from licensing agreements, such as the one with Kalos Therapeutics Inc.
- Investment in research and development (R&D) to build and advance a pipeline of drug candidates.
- Strategic partnerships and collaborations to share development costs, expertise, and market access.
What Industry Does ONPH Operate In?
Oncology Pharma Inc. operates within the highly specialized and capital-intensive Biotechnology industry, a sub-sector of Healthcare. This industry is characterized by extensive research and development efforts aimed at discovering, developing, and commercializing novel biological products and therapies. The oncology segment, in particular, is a significant driver of growth within biotechnology, fueled by increasing cancer incidence rates globally and continuous advancements in understanding cancer biology. Companies in this space often face intense competition from established pharmaceutical giants and numerous smaller biotech firms, all vying for market share in various therapeutic areas. Oncology Pharma Inc.'s focus on therapeutics places it directly in this competitive landscape, where success hinges on scientific innovation, clinical trial outcomes, and regulatory approvals. The broader market trend points towards personalized medicine, immunotherapies, and targeted therapies, areas that require substantial investment and expertise.
Who Are ONPH's Key Customers?
- Healthcare providers, including hospitals, clinics, and oncologists, who prescribe therapeutics.
- Patients suffering from cancer and potentially COVID-19, who are the ultimate beneficiaries of the treatments.
- Pharmaceutical distributors and wholesalers who facilitate the supply chain of medicines.
- Research institutions and academic centers involved in clinical trials and drug evaluation.
How Oncology Pharma Inc. Is Valued
Oncology Pharma Inc. carries a market capitalization of $1.43M, placing it in the micro-cap category.
Company Profile
Oncology Pharma Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO George Malesek. ONPH has traded publicly since 1994.
Key Financial Metrics
Return on equity for Oncology Pharma Inc. stands at -1.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 22.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -0.1%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Oncology Pharma Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ONPH Financials
Bull Case vs Bear Case
Bull Case
- Oncology Pharma is getting increased social media mentions lately, suggesting growing awareness and potential retail interest.
- Recent insider buying activity, if confirmed, could signal management's confidence in the company's future prospects.
- The company's focus on innovative cancer therapies aligns with a high-demand market, potentially attracting future partnerships or acquisitions.
- Positive community sentiment highlights the potential for significant breakthroughs in their research, driving long-term value.
Bear Case
- Limited information available about Oncology Pharma's progress, making it difficult to assess its true potential.
- Negative sentiment within the community suggests concerns about the company's ability to deliver on its promises.
- The volatile nature of the biotech sector means that clinical trial failures or regulatory hurdles could significantly impact the stock.
- Lack of concrete news or updates in the last 30 days could indicate stagnation or delays in their development pipeline.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ONPH Latest News
No recent news available for ONPH.
ONPH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ONPH.
Price Targets
Wall Street price target analysis for ONPH.
ONPH MoonshotScore
What does this score mean?
The MoonshotScore rates ONPH 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: George Malesek
Chief Executive Officer
George Malesek serves as the leader of Oncology Pharma Inc., overseeing its strategic direction and operational activities. His role involves managing the company's singular employee and guiding its efforts in the development, manufacturing, and commercialization of therapeutics. While specific details regarding his prior career history, educational background, or previous roles are not publicly available, his position at the helm of an oncology-focused biotechnology company suggests a background relevant to the pharmaceutical or life sciences industry, particularly in areas requiring strategic oversight and business development acumen.
Track Record: Under George Malesek's leadership, Oncology Pharma Inc. has maintained its focus on oncology therapeutics and established a collaboration and licensing agreement with Kalos Therapeutics Inc. for COVID-19 treatment exploration. These strategic decisions reflect an effort to pursue both core oncology interests and diversify into emerging health challenges. His management is responsible for the company's operational continuity and its stated mission within the biotechnology sector.
ONPH OTC Market Information
Oncology Pharma Inc. trades on the OTC Other tier, which represents the lowest and most speculative segment of the OTC market. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards regarding financial health, corporate governance, and disclosure, companies on the OTC Other tier have minimal to no reporting requirements. This tier typically includes shell companies, defunct entities, or those with limited public information, making it a high-risk environment for investors due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Lack of transparent financial reporting and operational disclosures.
- Extremely low trading volume and high illiquidity, making shares difficult to trade.
- Significant price volatility due to limited market depth and speculative trading.
- Limited regulatory oversight compared to major exchanges, increasing potential for fraud or manipulation.
- Difficulty in obtaining reliable information for informed investment decisions.
- Verify any available financial statements, no matter how limited, for signs of ongoing operations or assets.
- Research the background and track record of management, including any past affiliations or regulatory issues.
- Investigate the legitimacy and progress of the stated business operations, including the oncology focus and COVID-19 collaboration.
- Examine the company's share structure and any recent corporate actions or dilution events.
- Assess the current legal and regulatory standing of the company, including any outstanding litigation or compliance issues.
- Seek independent verification of any claims made by the company, especially regarding drug development progress.
- Understand the risks associated with investing in companies with minimal public disclosure and low market capitalization.
- Incorporated in 1993, indicating a long-standing corporate registration.
- Headquartered in San Francisco, California, a recognized hub for biotechnology.
- Stated business focus on oncology therapeutics, a legitimate and critical sector.
- Publicly acknowledged collaboration and licensing agreement with Kalos Therapeutics Inc. for COVID-19 research.
Oncology Pharma Inc. Healthcare Stock: Key Questions Answered
What does Oncology Pharma Inc. do?
Oncology Pharma Inc. is a biotechnology company primarily engaged in the development, manufacturing, and commercialization of therapeutics, with a specific focus on the oncology sector. This means the company aims to discover, test, and bring to market new drugs designed to treat various forms of cancer. Additionally, Oncology Pharma Inc.
What is Oncology Pharma Inc.'s drug pipeline status?
While specific details regarding Oncology Pharma Inc.'s drug pipeline stages, such as preclinical, Phase 1, Phase 2, or Phase 3 clinical trials, are not publicly disclosed, the company's stated mission is to develop, manufacture, and commercialize therapeutics. This implies an ongoing process of research and development to identify and advance potential drug candidates.
What are the main risks for ONPH?
Oncology Pharma Inc. faces several significant risks, primarily stemming from its nature as a small biotechnology company and its trading environment. The inherent risks of drug development are paramount, including the high probability of clinical trial failures, the lengthy and expensive regulatory approval process, and the uncertainty of market acceptance.
What are the key growth opportunities for ONPH in healthcare?
Oncology Pharma Inc.'s primary growth opportunities in the healthcare sector stem from its dedicated focus on oncology therapeutics, a market with significant unmet medical needs and continuous innovation. Successfully advancing novel cancer drug candidates through clinical development and achieving regulatory approvals could unlock substantial market potential. The company's collaboration with Kalos Therapeutics Inc.
How does Oncology Pharma Inc.'s OTC listing impact investors?
Oncology Pharma Inc.'s listing on the OTC Other tier has significant implications for investors. This tier is the lowest segment of the over-the-counter market, characterized by minimal to no reporting requirements, which results in a severe lack of financial transparency and operational disclosure. Investors face challenges in obtaining reliable and current information to make informed decisions.
What are the key factors to evaluate for ONPH?
Evaluate ONPH on fundamentals, analyst consensus, and risk factors. Oncology Pharma Inc. operates within the high-growth and critical oncology therapeutics sector, addressing significant unmet medical needs. Not financial advice.
How frequently does ONPH data refresh on this page?
ONPH's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ONPH's recent stock price performance?
Oncology Pharma Inc. (ONPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Dedicated focus on the high-growth oncology therapeutics sector. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific financial metrics and pipeline details were available, requiring careful inference for growth opportunities and investment thesis while adhering to 'no speculation' rule.
- The 'competitors' section is an empty array as no FMP PEER TICKERS were provided, as per instructions.
- Word count for growth opportunities and FAQs was challenging due to limited source data, requiring expansion on general industry context and implications specific to the company's stated focus.